To date, most of the studies have been done investigating the effects of miR-34 in NSCLC treatment due to its activity as a master tumor suppressor by silencing its multiple targets (e.g. CDK4, CDK6) involved in cell cycle regulation. This evidence concerns the gene CDK4 and non-small cell lung carcinoma.